Eli Lilly signs cancer research partnership worth up to $5.9 billion
Announced on 16 November, Eli Lilly has signed a research and licensing agreement with Cambridge based Stipple Bio to develop targeted cancer treatments. The agreement could be worth up to $5.9 billion through milestone payments and royalties. HPC could help connect biotechnology companies with pharmaceutical groups, research partners and investors.
If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.
Get in Touch
We’ll get back to you shortly.